Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.52 +0.18 (+0.12%)
Official Closing Price Updated: 4:10 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,891,477
Open 155.57
Bid (Size) 155.10 (2)
Ask (Size) 155.70 (1)
Prev. Close 155.34
Today's Range 154.57 - 155.93
52wk Range 150.11 - 181.04
Shares Outstanding 2,628,679,824
Dividend Yield 3.06%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
Benzinga 
Via Benzinga
Johnson & Johnson Sees Legal Win In Talc Powder Cancer Claims
A New Jersey appeals court overturned a $223.8 million verdict linked to asbestos exposure in Johnson & Johnson's (NYSE: JNJ)  
Via Benzinga

Performance

YTD
-12.72%
-12.72%
1 Month
-3.21%
-3.21%
3 Month
-4.48%
-4.48%
6 Month
-1.87%
-1.87%
1 Year
-4.71%
-4.71%

More News

Read More
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
Via Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Via Benzinga
Looking At Johnson & Johnson's Recent Unusual Options Activity
Via Benzinga
Higher Rates, Lower Leverage: Growth Stocks To Struggle While AI Offers Hope, Goldman Sachs Analysts Say
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
Via Benzinga
Johnson & Johnson Urged To Expand Access Tuberculosis Medication
Via Benzinga
Could Kenvue Follow in the Footsteps of Johnson & Johnson and Become a Top Dividend Stock?
Via The Motley Fool
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
Is Kenvue Stock Too Pricey to Buy?
Via The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
Via The Motley Fool
Recession-Proof Royals: 3 Stocks That Thrive in Tough Economic Times
Via InvestorPlace
Don’t Miss Out: 3 Dividend Stocks to Buy on EVERY. SINGLE. DIP.
Via InvestorPlace
These 7 Dividend Stocks Pay $98 Billion Annually, Combined, to Their Shareholders
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs
Via Benzinga
What's Going On Pfizer's Subsidiary Biohaven Stock?
Via Benzinga
Why Immunovant Stock Is Bolting Higher Today
Via The Motley Fool
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
Via Benzinga
3 Things About Johnson & Johnson That Smart Investors Know
Via The Motley Fool
2 Monster Stocks to Buy Without Any Hesitation
Via The Motley Fool
3 Blue Chip Safe Havens to Shield Your Portfolio
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
3 Reasons SharkNinja Is Swimming Toward New Highs
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.